![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2022/07/06/2474791/0/en/Zenith-Epigenetics-Announces-Start-of-Several-National-Cancer-Institute-NCI-Sponsored-Oncology-Clinical-Trials.html
https://www.globenewswire.com/news-release/2022/06/21/2465992/0/en/Zenith-Epigenetics-Triple-Negative-Breast-Cancer-Clinical-Data-Highlighted-in-an-Oral-Discussion-at-the-American-Society-of-Clinical-Oncology-Conference-ASCO.html
https://www.clinicaltrialsarena.com/news/zenith-breast-cancer-trial/
https://www.globenewswire.com/news-release/2022/05/10/2439733/0/en/Zenith-Epigenetics-Announces-Initiation-of-a-Phase-2b-Triple-Negative-Breast-Cancer-TNBC-Clinical-Trial.html
https://www.biospace.com/article/releases/zenith-epigenetics-announces-dosing-of-first-cancer-patient-with-a-combination-of-zen-3694-bristol-myers-squibb-s-immune-checkpoint-inhibitor-opdivo/
https://www.globenewswire.com/news-release/2021/08/17/2281942/0/en/Zenith-Epigenetics-Announces-a-Publication-in-the-Journal-of-Cancer-Gene-Therapy-with-Compelling-Data-for-the-Treatment-of-ER-Positive-Breast-Cancer-Patients.html
https://www.globenewswire.com/news-release/2021/06/24/2252528/0/en/Zenith-Epigenetics-Announces-a-Publication-Highlighting-the-Role-of-ZEN-3694-in-Overcoming-Resistance-to-Therapies-in-Metastatic-Castration-Resistant-Prostate-Cancer.html
https://www.globenewswire.com/fr/news-release/2021/04/22/2214989/0/en/Zenith-Epigenetics-Announces-Clinical-Collaboration-with-Astellas.html#:~:text=Zenith%20Epigenetics%20Announces%20Clinical%20Collaboration%20with%20Astellas,-To%20Evaluate%20the&text=(%E2%80%9CAstellas%E2%80%9D)%20to%20evaluate,resistant%20prostate%20cancer%20(mCRPC).
https://www.globenewswire.com/news-release/2020/10/05/2103471/0/en/Zenith-Epigenetics-Announces-Collaboration-with-NCI-in-Developing-ZEN-3694-for-Multiple-Oncology-Indications.html
https://www.globenewswire.com/news-release/2020/07/29/2069378/0/en/Zenith-Epigenetics-Advances-ZEN-3694-in-Multiple-Cancer-Programs.html